

**Supplementary material**


**Figure S1 —** Vaccine uptake, from week 1 to 26 of 2021 in Mainland Portugal




**Figure S2** — Number of people vaccinated with mRNA vaccine by brand, from week 1 to 26 of 2021 in Mainland Portugal



**Figure S3** — mRNA vaccine coverage per age group and week, from week 1 to 26 of 2021 in Mainland Portugal



**Figure S4 —** Relative frequency of age groups of reported confirmed cases over 40 years to the national surveillance system and study sample, from week 20 to 26 of 2021 in Mainland Portugal



**Case-case study design description**

The most common approach of vaccine effectiveness (VE) studies is test-negative case-control design, where VE is estimated comparing odds of vaccination between positive (cases) and negative (controls) (VE=(1-OR)\*100%).

Variant-specific vaccine effectiveness estimates in test-negative design (TND) studies are obtained restricting comparisons to cases positive to specific variant versus negative controls (Table S1)

**Table S1** — Classification of cases by vaccination and positivity status

|  |  |  |  |
| --- | --- | --- | --- |
|  | Delta+ | Alpha+ | Negative controls |
| Vaccinated | a | k | b |
| Unvaccinated | c | m | d |

resulting in vaccine effectiveness estimates

and, ,

where and are obtained as follows:

Only positive cases are considered in case-case design, and odds of vaccination are compared directly between two variants. Considering Delta cases as cases of interest and Alpha cases as a reference group, the case-case OR is estimated as:

that is mathematically equivalent to the ratio of two variant-specific OR obtained from TND:

= ==

The case-case approach allows to formally test whether the difference between variant-specific odds ratios is statistically significant and infer variant-specific vaccine effectiveness (Figure S5).

**Figure S5** — Comparison diagram between test-negative design and case-case design

